T-Curx
t-curx.com
Health Care
Cell & Gene Therapy
Biotechnology
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$20M
1 round on record
Latest round
$20M
Series A · Dec 2025 · 9 mo ago
Backers
1
Bayern Kapital
The money's age
Fresh money
9 months since the last round · not hiring
Momentum
35/100
in the news, fresh money
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Dec 24, 2025
Raised a round Series A $20M · Pulse 2.0
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series A | Dec 2025 | $20M | — | Pulse 2.0 |
Registers and programsofficial lists and records that name the company
| Legal entity | X GmbH. T-CURX GmbH | its site |
Founders and leadersfrom filings, registers and the company's site
Scientific AdvisoryDirectorscompany's site
Backed byfrom the funds' portfolios and accelerator catalogs
Bayern Kapital Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Cancer immunotherapy that turns cancer cells into biofactories minting their own destruction.
Adventris Pharmaceuticals is a biotechnology company focusing on cancer immunotherapy.
At CellVax Therapeutics, we are developing the Next Generation of Personalized Immunotherapy.
Reprogramming is the next leap forward in cancer immunotherapy. Asgard Therapeutics is a Swedish private biotech company exploring direct…
MediSix Therapeutics develops innovative T-cell therapies using its proprietary PEBL technology platform. An IASO Biotechnology subsidiary.
Invest in cutting-edge immunotherapy solutions targeting cancers and rheumatic diseases.
Overview
T-CURX develops a new generation of T cells for personalized cancer immunotherapy, built on a proprietary platform that overcome challenges ...
News
Kytopen, T-CURX, and the Fraunhofer IZI Establish Center of Excellence to Develop Advanced, Non-viral Cell Therapies
Kytopen partners with T-CURX and the Fraunhofer Institute for Cell Therapy and Immunology (IZI) in Würzburg and Leipzig, Germany to establish a joint Center of...
Read more
Report
T-CURX: $20 Million Series A First Closing Raised To Advance Non-Viral CAR-T Pipeline And In Vivo Platform
T-CURX GmbH said it has completed the first closing of a $20 million (€17.7 million) Series A financing to accelerate the clinical development of its non-viral CAR-T programs in acute myeloid leukemia and solid tumors, while advancing proprietary technolo
Read more
Report
T-CURX获得2000万美元A轮融资_腾讯新闻
T-CURX 是一家CAR-T细胞疗法开发商专注于开发和商业化下一代CAR-T细胞疗法用于治疗医疗需求高的癌症适应症该公司的专有CAR-T技术总部位于德国是在维尔茨堡大学联合创始人Michael Hudecek教授的实验室中开发的其核心是一种新型睡美人
Read more
Report
T-CURX GmbH Enters into Technology Access Agreement with Kytopen
Kytopen Corp., a leader in providing non-viral, continuous flow cellular engineering technologies, and T-CURX GmbH ("T-CURX"), a leader in non-viral, transposon-based CAR-T manufacturing for the treatment of cancer, today announced the execution of a join
Read more
Report
People
Scientific Advisory
Directors
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Financials
Total raised
$20M
Latest round
Series A
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series A | 2025 | $20M | Details |